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PROTEASE inhibitors have been shown
to inhibit tumour growth (Latner et al.,
1974; Verloes et al., 1978) and invasiveness
(Latner et al., 1973) in animal model
systems. In addition, other recent evi-
dence (Latner & Turner, 1976; Burden et
al., 1978) has suggested that these sub-
stances may be operating in cancer by
stimulating the host's immunological re-
sponse. In view of these observations, we
decided to investigate the in vitro effect
of the protease inhibitor aprotinin (Trasy-
lol®) on the response to PPD (purified
protein derivative of Mycobacterium tuber-
culosis) of human peripheral lympho-
cytes from cancer patients and from
non-tumour-bearing individuals using the
Tanned Erythrocyte Electrophoretic
Mobility (TEEM) test (Shenton et al.,
1977).
Heparinized venous blood was obtained
from 4 groups of individuals. The 1st
group ("Healthy") consisted of 10 volun-
teers who were clinically fit. The 2nd
group ("Post-Operative") consisted of 6
patients who had undergone moderate
intra-abdominal surgery 10 days pre-
viously for benign conditions. The 3rd
group ("Operable Carcinoma") consisted
of 7 patients who had undergone a
"curative" resection of an adenocarcinoma
of the stomach with removal of all macro-
scopic tumour. The 4th group ("Inoper-
able Carcinoma") consisted of 9 patients
who had a carcinoma of the stomach
which at laparotomy had been unresect-
able. Blood specimens were withdrawn
in the latter two groups 5- 0 days after
operation.
Peripheral lymphocytes were isolated
from whole blood using the density-
gradient centrifugation technique des-
cribed by Boyum (1968). For each prep-
aration of lymphocytes 3 tubes were set
up, each containing 0 5 x 106 cells. The
1st tube (a) contained no other additive,
the 2nd tube (b) contained 0-1 mg PPD,
and the 3rd tube (c) contained the same
amount of PPD plus 10 units of apro-
tinin. The final volume in each tube was
made up to 3 ml with Hank's balanced
salt solution. After standing at room
temperature for 1 h, lymphocytes were
removed by centrifugation, and 108 tanned
sheep erythrocytes, in 0.2 ml Hank's bal-
anced salt solution, added to each super-
natant. After standing for a further hour,
the presence of the erythrocyte-slowing
factor was assessed by measuring the
mobility of the supernatant-treated cells
in a Zeiss cytopherometer. Mobilities
were expressed in terms of the mean
time taken for 20 cells to move over a set
distance. Percentage slowing (0o S) was
calculated from the formula:
(Tb or Tc) Ta
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where Ta, Tb and Tc are the mean times
(sec) for erythrocytes treated with super-
natants from tubes a, b or c respectively.
This method of assessing lymphocyte
response to antigens has been called the
TEEM test (Shenton et al., 1977).
Differences between groups were ana-
lysed statistically using Student's t test.
At the concentration of aprotinin used
in these studies (3.3 u/ml) no significant
change in erythrocyte mobility could be
detected either after incubating the ery-
throcytes directly with the aprotinin or
after treating the erythrocytes with super-
natant from lymphocytes which had been
treated with aprotinin only.
TABLE I.-TEEM-Test results for peri-
pheral lymphocytes exposed to PPD in
vitro
Patient group
Healthy (10)
Post-operative (6)
Operable carcinoma (7)
Inoperable carcinoma (9)
% Slowing
mean s.e.
17-8 1-3
11-0 0-4
12-2 1-1
14-1 1-0
<I
TABLE II.-TEEM-Test results for peri-
pheral lymphocytes exposed to PPD and
aprotinin in vitro
% Slowing
t
Patient group mean
Healthy (10) 24-5
Post-operative (6) 15- 7
Operable carcinoma (7) 23-7
Inoperable carcinoma (9) 23 *5
n s.e.
1*4
0 7
1 9
2-3
p
<0-001
>0 05
>0 05
marked in the "Post-Operative" group.
The elevated values obtained for the
other three groups were very similar to
each other (P > 0.05).
TABLE III.-In vitro effect of aprotinin on
the response ofperipheral lymphocytes in
the TEEM-Test
% Increase* in
lymphocyte
response
A-
Patient group
p Healthy (10)
Post-operative (6)
Operable carcinoma (7)
0 001 Inoperable carcinoma (9)
0 v-v0
<0 *025
In Tables I to III the figure in parentheses indi-
cates the number of individuals in each group, and
P the level of significance as compared with the
healthy group; P for other comparisons is in the
text.
Table I shows the TEEM-test results
for peripheral lymphocytes exposed to
PPD. Lymphocytes from "Healthy" indi-
viduals produced the greatest response,
viz. greatest % S. For all the other groups,
the response was diminished, and signi-
ficantly less than in the healthy group.
Comparison of the "Post-Operative" and
"Operable Carcinoma" groups indicated
no significant difference (P > 0 05). How-
ever, the response ofthe "Post-Operative"
group was significantly lower (P < 0 025)
than that of the "Inoperable Carcinoma"
group.
Table II shows the 'TEEM test' results
for peripheral lymphocytes exposed to
PPD and aprotinin. In all groups, the
inclusion of aprotinin significantly in-
creased the response of lymphocytes to
PPD (P < 0.05). This effect was least
mean s.e. P
37-1 4-5
43-6 6-7
88-4 10-6
65-6 9 3
>0*05
<0*0005
<0-01
* Calculated for each individual using the follow-
ing formula:
(Oo SPPD + Aprotinin)
- % SPPD X 100
% SPPD
Table III combines the data in Tables
I and II and gives the percentage increase
in lymphocyte response to PPD pro-
duced by treatment with aprotinin. It
can be seen that the percentage increases
for the "Healthy" and "Post-Operative"
groups are not significantly different.
On the other hand, in both "Carcinoma"
groups the percentage increase is very
significantly higher than in the "Healthy"
group.
Our results indicate that aprotinin can
considerably stimulate the response to
PPD of peripheral lymphocytes from
cancer patients. This stimulation was
shown to be more a process of restoration
to normal levels of a depressed immuno-
logical response than a specific stimula-
tion of the cancer lymphocytes. Both
surgical trauma and/or the presence of
cancer resulted in lymphocyte depression
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in the TEEM test in the absence of apro-
tinin. This confirms findings from other
studies with different techniques (Riddle
& Berenbaum, 1967; Turnbull & Cooper,
1975). Although these two conditions
produce the same end result they do not
appear, from our data, to achieve it by a
similar mechanism. Firstly, depressive
effects were not additive, because the
mean % S for the "Operable Carcinoma"
group, in which surgical trauma was con-
siderable, was not less than that in the
"Post-Operative" group. Secondly, the
aprotinin - stimulated response of the
"Post-Operative" group was much less
than that of the cancer groups, and even
less than that of untreated "Healthy"
lymphocytes. In other words, aprotinin
treatment did not restore "Post-Opera-
tive" lymphocytes to a normal functional
level, as judged by the TEEM test,
whereas cancer lymphocytes were com-
pletely restored.
The precise role of protease inhibitors
in lymphocyte stimulation is still very
unclear. Our findings of general stimula-
tion by aprotinin treatment support those
recently reported by Burden et al. (1978)
using the leucocyte migration test. In
contrast, Hirschhorn et al. (1971) have
reported inhibition by several synthetic
protease inhibitors, including EACA, of a
number of parameters associated with
lymphocyte stimulation. It may be that
the effect of aprotinin on lymphocytes is
dose dependent. To support this idea,
published data (Thomson et al., 1978)
have shown that aprotinin, at concentra-
tions ofthe same order that we have used,
slightly stimulates PHA and ConA-acti-
vated lymphocyte transformation as mea-
sured by [3H] TdR incorporation, whereas
at higher concentrations the effect appears
to be one of inhibition.
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